IP Library › Granted Patent US 12,685,734
Granted Patent B2
US 12,685,734 · App. 17/968,386 · Granted Jul 21, 2026

N6-methyladenosine regulators in uterine fibroids

Inventors: Qiwei Yang (Bolingbrook, IL); Ayman Al-Hendy (Hinsdale, IL)
Assignee: The University of Chicago
A61K31/519A61K35/768A61K38/44A61K38/45A61P35/00C12N15/1137C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,685,734
App. No.
17/968,386
Granted
Jul 21, 2026
Kind
B2
Abstract

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an agent that modulates an N6-methyladenosine (m6A) regulator.

Claims (2)

1 . A method of treating a uterine fibroid in a female mammal, the method comprising administering to the female mammal an effective amount of an agent that inhibits an N6-methyladenosine (m6A) regulator, wherein the m6A regulator is an m6A writer, and wherein the agent is STM2457.

2 . A method of treating a uterine fibroid in a female mammal, the method comprising administering to the female mammal an effective amount of an agent that inhibits an N6-methyladenosine (m6A) regulator, wherein the m6A regulator is an m6A writer, wherein the agent is a lentivirus, wherein the m6A writer is methyltransferase-like 3 (METTL3), wherein the lentivirus knocks down the METTL3, and wherein the lentivirus is a shMETTL3 lentivirus.